Please login to the form below

Not currently logged in
Email:
Password:

commercial

This page shows the latest commercial news and features for those working in and with pharma, biotech and healthcare.

Bayer picks digital firms for open innovation support

Bayer picks digital firms for open innovation support

products. Reinhard Franzen, head of Bayer Pharmaceuticals Commercial Operations Europe, Middle East and Africa, said: “We recognise the huge creative potential outside Bayer and we believe that combining expertise is key

Latest news

  • Antibiotic resistance to lead to millions of deaths Antibiotic resistance to lead to millions of deaths

    to improve the commercial viability of new antibiotics and encourage responsible use of existing drugs.

  • Be suspicious of great results Be suspicious of great results

    As commercial leaders and front-line managers, we assume that we are doing well because we have the right strategy and execution. ... Did a competitive product go on backorder? Was there a change (for better or worse) in the reimbursement or market

  • US R&D hit in GSK's latest cost-cutting round US R&D hit in GSK's latest cost-cutting round

    Mary Anne Rhyne, GSK's director of US external communications, said in a statement that the company is "reshaping and reducing the size of our commercial and R&D operations (now ... in the US R&D and commercial functions by the end of 2015, she confirmed.

  • Excellence in pharma launches Excellence in pharma launches

    All pharmaceutical commercial personnel understand the critical importance of the first few months of any product launch. ... However, today's commercial challenge is to identify that 'reason to change' in an evidence-based, outcome driven,

  • AZ and Cancer Research UK to collaborate on new medicines AZ and Cancer Research UK to collaborate on new medicines

    CRUK will decide which novel cancer drug discovery projects to pursue while AZ has the option to negotiate commercial licensing rights with Cancer Research Technology, CRUK's commercial branch.

More from news
Approximately 1 fully matching, plus 1,001 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    the low commercial value placed on antibiotic drugs compared to more lucrative sectors such as cardiovascular disease and cancer. ... We now need international action to establish mechanisms such as Market Entry Rewards for new drugs that might never

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    In particular, it outlines the need for industry to take on bold, far-sighted ambitions in the life science industry with the intention of creating commercial success underpinned by novel technology

  • Health on instalment Health on instalment

    For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option. ... Even cutting prices by half - an unlikely event in a land as keen on commerce as the US - would still leave such treatments well outside

  • The rise of real-world evidence The rise of real-world evidence

    commercial strategies for years to come.

  • Bridging pharma’s digital gap Bridging pharma’s digital gap

    senior vice president of commercial strategy, told PME at Veeva’s recent European Commercial &Medical Summit in Madrid. ... Aside from the need to negotiate regulatory barriers compliance rules, David Bennett, Veeva’s European VP for commercial

More from intelligence
Approximately 0 fully matching, plus 218 partially matching documents found.

Latest appointments

  • Abeona Therapeutics names CEO Abeona Therapeutics names CEO

    Formerly serving as Alexion Pharmaceutical’s executive vice president and chief commercial officer, Thiel brings experience in leading commercial operations to his new position. ... In his recent positions, he successfully created value by building

  • Neurocentrx appoints two members to the board Neurocentrx appoints two members to the board

    Brooksby said: “My focus is to accelerate the business model and drive commercial clinical trials to raise international awareness of what we are offering, and enter the global market.

  • Novo Nordisk appoints new general manager Novo Nordisk appoints new general manager

    Sahota, who brings experience from business, commercial and leadership roles to Novo, was most recently responsible for creating commercial and market development strategies across Europe as senior vice president of market ... Sahota started his

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    acquisition of drug candidates, commercial products and companies for the global speciality drug business.

  • David Colpman joins Forendo Pharma’s board David Colpman joins Forendo Pharma’s board

    His previous roles include head of global business development at Shire and business development and commercial positions at Glaxo Wellcome - now GlaxoSmithKline - and Novo Nordisk. ... His insights and expertise will be very helpful as we continue to

More from appointments
Approximately 1 fully matching, plus 304 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 299 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics